Publications by authors named "J Cosaert"

Claim this Profile
K
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer.
Ana Galan-Cobo, Natalie I Vokes, Yu Qian, David Molkentine, Kavya Ramkumar, Jan Cosaert

Cancer Cell· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer.
Neil H Segal, Jeanne Tie, Scott Kopetz, Michel Ducreux, Eric Chen, Jan Cosaert

Br J Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, Sylvia Hartl, Patrick M Forde, Jan Cosaert

Nat Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours.
Melissa L Johnson, Judy S Wang, Gerald Falchook, Carol Greenlees, Suzanne Jones, Jan Cosaert

Br J Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
Thomas Powles, Danielle Carroll, Simon Chowdhury, Gwenaelle Gravis, Florence Joly, Jan Cosaert

Nat Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis